Roche is expanding its cancer modality bets with a new pact that merges antibody-drug conjugation and targeted protein degradation. In a collaboration with C4 Therapeutics, Roche agreed to pay $20 million upfront and commit more than $1 billion in milestones to develop degrader-antibody conjugates (DACs) for two undisclosed oncology targets. Under the deal, Roche and C4 will select and design antibody components and degrader payloads using C4’s Torpedo platform, then advance DAC candidates through preclinical development and beyond. The agreement also includes an option to add a third target. Separately, reports also highlighted deal activity across the degrader ecosystem, with Gilead exercising licensing rights on Kymera Therapeutics’ preclinical CDK2 molecular-glue degrader KT-200. Together, the agreements underscore how big pharma is leaning into protein degradation–enabled payload delivery to address undruggable targets and improve therapeutic windows.